BGI
TSHA icon

B Group Inc’s Taysha Gene Therapies TSHA Stock Holding History

B Group Inc’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3M Hold
1,800,556
– – 5.76% 6
2026
Q1 		$8.05M Hold
1,800,556
– – 5.97% 6
2025
Q4 		$9.9M Hold
1,800,556
– – 7.31% 4
2025
Q3 		$5.89M Hold
1,800,556
– – 4.33% 7
2025
Q2 		$4.16M Buy
1,800,556
+545,000
+43% +$1.18M 3.2% 7
2025
Q1 		$1.75M Buy
1,255,556
+290,000
+30% +$485K 1.5% 10
2024
Q4 		$1.67M Buy
+965,556
New +$2M 1.02% 10

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

B Group Inc's TSHA Position: Q2 2026 in Review

B Group Inc held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 1,800,556 shares worth $12.3M. The position accounts for 5.76% of the portfolio, ranked #6.

B Group Inc first reported a position in TSHA in Q4 2024 and has held it in 7 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • B Group Inc held 1,800,556 shares of Taysha Gene Therapies worth $12.3M as of Q2 2026.
  • B Group Inc left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up 5.76% of B Group Inc's portfolio in Q2 2026, its #6 holding.
  • B Group Inc first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 7 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.